<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客研究院 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-19T12:12:37+08:00</updated>
  <subtitle>独立报告、专业分析、深度解读</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>丽珠：从传统迈向创新｜大话JPM</title>
    <updated>2021-01-18T21:28:15+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/iUirg8QjY5btIT0dukvUfA</id>
    <link href="https://mp.weixin.qq.com/s/iUirg8QjY5btIT0dukvUfA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Rhythm：治疗罕见遗传性肥胖一枝独秀 | 公司</title>
    <updated>2021-01-18T11:07:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/pDyB7LLauSThQhA7Z3RN0w</id>
    <link href="https://mp.weixin.qq.com/s/pDyB7LLauSThQhA7Z3RN0w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再鼎：三项交易继续买买买 | 大话JPM</title>
    <updated>2021-01-15T10:19:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/tftVcNhMC5AuBDX-sLCs_Q</id>
    <link href="https://mp.weixin.qq.com/s/tftVcNhMC5AuBDX-sLCs_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物：有望成为首个在美递交BLA的国产PD-1 | 大话JPM</title>
    <updated>2021-01-15T10:19:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/qPhtHkSL9rjlLx6OnpYFhg</id>
    <link href="https://mp.weixin.qq.com/s/qPhtHkSL9rjlLx6OnpYFhg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>和誉医药：自建一体化靶点和药物发现平台 | 大话JPM</title>
    <updated>2021-01-15T10:19:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/XZHqmxrNvejnAKis02EfKA</id>
    <link href="https://mp.weixin.qq.com/s/XZHqmxrNvejnAKis02EfKA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三生制药：32项在研产品覆盖五大领域 | 大话JPM</title>
    <updated>2021-01-14T12:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/bRtVsb-5MUDVL6CXyWGyRA</id>
    <link href="https://mp.weixin.qq.com/s/bRtVsb-5MUDVL6CXyWGyRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>和黄医药：进入三驾马车时代 | 大话JPM</title>
    <updated>2021-01-14T12:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/fgogTaJtXqV1-aNqbI52xw</id>
    <link href="https://mp.weixin.qq.com/s/fgogTaJtXqV1-aNqbI52xw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药：快速推进第一个产品上市｜大话JPM</title>
    <updated>2021-01-14T12:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/RR3WPM7h7bTM6rdVBqPg7Q</id>
    <link href="https://mp.weixin.qq.com/s/RR3WPM7h7bTM6rdVBqPg7Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>君实生物：特瑞普利单抗有望成为最快在美上市的国产PD-1 ｜大话JPM</title>
    <updated>2021-01-14T12:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/dRZHzVZQcd4gkMPXTE4Mhw</id>
    <link href="https://mp.weixin.qq.com/s/dRZHzVZQcd4gkMPXTE4Mhw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>岸迈生物：基于FIT-lg平台的双抗开发 ｜大话JPM</title>
    <updated>2021-01-14T12:59:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/DFoTaGPM3AQ7CqCpRs_YUA</id>
    <link href="https://mp.weixin.qq.com/s/DFoTaGPM3AQ7CqCpRs_YUA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Curis股价飙升4倍，IRAK4抑制剂受到关注 | 公司</title>
    <updated>2021-01-07T14:17:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/HnD2Q2QPLWQNVb1nCrkzZg</id>
    <link href="https://mp.weixin.qq.com/s/HnD2Q2QPLWQNVb1nCrkzZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NK细胞疗法在研项目梳理 | 分析</title>
    <updated>2020-12-29T18:42:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/4tRBNmPbXj_mLhSggMCObg</id>
    <link href="https://mp.weixin.qq.com/s/4tRBNmPbXj_mLhSggMCObg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“医药代表备案制”正式落地，MAH成为责任主体 | 观点</title>
    <updated>2020-12-29T11:18:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/sQOf2_F9uwvHnsyC7ikMeA</id>
    <link href="https://mp.weixin.qq.com/s/sQOf2_F9uwvHnsyC7ikMeA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>凭借新冠治疗药物名噪一时的AbCellera｜公司</title>
    <updated>2020-12-28T11:21:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/wsTA_3nw4bLooFsuiFWp3A</id>
    <link href="https://mp.weixin.qq.com/s/wsTA_3nw4bLooFsuiFWp3A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>只有一个候选产品却能顺利融资的Olema｜公司</title>
    <updated>2020-12-24T12:34:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/asOaCzChbUtiYNnzqVF7ew</id>
    <link href="https://mp.weixin.qq.com/s/asOaCzChbUtiYNnzqVF7ew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PSR filing system landed</title>
    <updated>2020-12-22T16:01:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/va4MSsZ6i7aLSuL2lK2Pdg</id>
    <link href="https://mp.weixin.qq.com/s/va4MSsZ6i7aLSuL2lK2Pdg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>